Sunday, May 5, 2024
5/5/2024
ABSTRACT: Infertility impacts 48 million couples worldwide and 50% of cases are due to a male factor. Non-obstructive azoospermia (NOA) is the absence of sperm due to spermatogenic failure. Some cases are due to known conditions (Klinefelter’s Syndrome, Y chromosome microdeletions, and hypogonadism) but many cases are idiopathic (unexplained). Recent identification of novel monogenic causes of NOA sparks the possibility of gene therapy as a potential treatment option. There are ethical, legal and societal concerns about gene therapy approaches that would modify the germline and potentially be passed to progeny. Therefore, development of gene therapy approaches for male infertility should consider the risk of germline modification and transmission. Sertoli cells are the only testicular somatic cells that are inside the seminiferous tubules and in direct contact with the germ cells and Sertoli cell mutations can lead to NOA in both mice and humans. I will test the feasibility and safety of in vivo Sertoli cell gene therapy in mouse models of human NOA. Adeno-associated virus (AAV) is an optimal vector for Sertoli cell gene therapy because there are many AAV serotypes with cell type specificity of infection, it can have long lasting expression, it has low toxicity in the testis, and does not typically integrate into the genome. AAV has been used to introduce a corrective Kitl gene into Sertoli cells of Kitl-/- mice that have an NOA phenotype, restoring spermatogenesis. In humans, mutations in the KITL gene do not cause infertility. Under separate funding, our group has been performing whole genome or whole exome sequencing to identify genetic variants in men with NOA. I have screened those data to identify NOA-associated variants in MAP7 and CLCN2 that are expressed by Sertoli cells and cause NOA when knocked out in mice. I will use CRISPR/Cas9 gene editing to introduce the patient variants into the orthologous regions of the mouse genome to create new mouse models of human NOA. I will use these models to test the hypothesis that, fertility can be safely restored by AAV-mediated Sertoli cell gene therapy and that this can be accomplished without germline modification or transmission to progeny. To facilitate the translation of this technology toward the human clinic, I will utilize a novel human testis organ culture technique to identify AAV serotypes that exhibit Sertoli cell specific infection in human testicular tissue. Completion of my project will demonstrate the safety and feasibility of Sertoli cell gene therapy using AAV vectors. I will uncover new knowledge into genetic causes of Sertoli cell dysfunction and propose a technique that can test other aspects of AAV use in human tissue. Overall, the completion of this grant will greatly increase my technical research skills in gene therapy and male infertility in a bench to bedside research pipeline. This will provide a strong foundation of knowledge and skills to prepare me for a career as a faculty and independent researcher in academia.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
